PCFiT™ Recombinant Protein Technology is Worg's globally exclusive AIT drug development platform. By identifying the corresponding sensitizing protein T-cell and B-cell epitopes based on allergen characteristics, it produces peptide carrier fusion proteins that efficiently induce protective immune responses, achieving optimal IgG immunogenicity and, thus, safer and more effective allergy immunotherapy.
Compared to traditional allergen-extracted AIT drugs, PCFiT™ recombinant proteins offer outstanding advantages, including high IgG induction efficacy, minimal side effects, and ease of use.
Early clinical data show that patients treated with PCFiT™ AIT drugs require only 3-5 doses to achieve long-term relief from allergy symptoms.
WP1075 is a biopharmaceutical designed to treat cat dander allergies. Pet dander is one of the fastest-growing allergens globally, with the latest epidemiological data indicating that nearly 20% of AR patients in China are allergic to pet dander.
The active ingredient of WP1075 is developed using AI algorithms to screen antigen sequences, identify the final candidate peptide core inducing epitopes, and complete spatial reconstruction.
Preclinical studies have demonstrated a significant ability to block the binding of antigens to IgE and induce specific IgG immune responses. Treatment can be completed with just 2-3 injections, significantly improving the accessibility of AIT.
The drug's PCC has been completed and is about to enter clinical trials.
Scan
WeChat official account
A wholly-owned subsidiary of Worg PHARMA
